VC-backed Concert Pharmaceuticals files for IPO – Fortune

Fortune reported that Concert Pharmaceuticals has filed for a $74.75 million IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol “CNCE.” UBS and Wells Fargo are the lead underwriters. Based in Lexington, Mass., Concert Pharmaceuticals produces drugs that treat spasticity and kidney disease. Its backers nclude Three Arch Partners, TVM Capital, GlaxoSmithKline, Brookside Capital, Skyline Ventures, Fidelity Investments, Greylock Partners and Flagship Ventures.